FEATURE ARTICLES
Several advantages explain why Puerto Rico continues to attract pharma investment, especially as manufacturers reassess supply chain risk and look for options closer to the U.S. mainland.
- CDMO Live Europe 2026: Partnerships For An Uncertain World
- Resilience, Risk, And Relationships: CDMO Live Europe 2026 Report
- Building AI Readiness Through Cross Collaboration
- Bayer Adds A Spine To Modularity For Scale Without Disruption
- 7 Facilities Pilot PreCheck for Faster Approval
- Bridging The Atlantic: A European Executive's Guide To Entering The U.S. RNA Market (Pt. 1)
- Transforming Computer System Validation In The Life Sciences Industry
PHARMA ONLINE WHITE PAPERS
-
![GettyImages-931069642 mAb, monoclonal antibodies]( "Leveraging 3 Distinct Resins To Provide Effective Impurity Removal For mAbs And Novel Antibody Derivatives")
Leveraging 3 Distinct Resins To Provide Effective Impurity Removal For mAbs And Novel Antibody DerivativesDue to the complexity of bispecifics, Fc-fusion proteins, and Fab fragments, their manufacturing poses added purification challenges and requires a robust toolkit of purification techniques.
-
Pharmaceutical Spray Drying – Technology And Applications1/21/2025
Explore the transformative potential of pharmaceutical spray drying in improving drug formulation, bioavailability, and delivery through versatile and innovative applications.
-
OEE And Product Inspection2/13/2025
Explore the calculation of Overall Equipment Effectiveness (OEE) and the impact of product inspection equipment on OEE in the pharmaceutical industry.
-
Alleviate Compliance Risks With Your EAM/CMMS3/2/2026
Discover how unified asset management enhances audit readiness by connecting maintenance, calibration, and quality insights, as well as how integrated workflows reduce compliance risk.
-
AI Implementation To Enhance Quality2/11/2025
Discover how solutions driven by artificial intelligence can enhance compliance, optimize workflows, and drive efficiency in biopharma operations.
-
The TIDES Manufacturing Mandate: Why Incrementalism Fails And Integration Prevail5/7/2026
Manufacturing strategies for peptides and oligonucleotides are being reshaped by scale, complexity, and chronic use. An integrated, end‑to‑end approach shows how early design decisions can prevent costly bottlenecks later.
PHARMA ONLINE APP NOTES & CASE STUDIES
NEWSLETTER ARCHIVE
- 08.06.26 -- Analyzing And Managing CDMO Project Risks Using Causal Mechanism And Effect Analysis
- 08.06.26 -- Starting Material Importance
- 08.05.26 -- Platform Strategies For Manufacturable Bispecific Antibodies
- 08.04.26 -- Preparing For What's Next In Regulated Manufacturing
- 08.04.26 -- Building AI Readiness Through Cross Collaboration
INDUSTRY NEWS
-
![white coupon banner, great topic-GettyImages-2271702407]( "Let Your Voice Help Shape Pharma Manufacturing")
Let Your Voice Help Shape Pharma ManufacturingPharmaceutical Online hosts live virtual panels with industry experts on important topics and challenges, and we want to know what topics are important to you. Please consider taking a few minutes of your time to tell us what they are.
-
![rating service, satisfaction-GettyImages-2221603596]( "ISPE Announces 2026 FOYA Winners")
ISPE Announces 2026 FOYA WinnersThese awards recognize pharmaceutical and biopharmaceutical manufacturing projects that demonstrate excellence across innovation, operations, supply chain, Pharma 4.0, and social impact.
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
STERIS To Invest $600 Million To Build Center Of Excellence In North Carolina8/6/2026
STERIS plc today announced that it will be investing $600 million to build a formulated chemistries manufacturing and distribution Center of Excellence in North Carolina, near the Raleigh-Durham Research Triangle region. The facility will serve as a central hub to produce high-performance infection prevention and contamination control chemistries used across the Healthcare and Pharmaceutical industries.
-
BeOne Committing $1 Billion+ To U.S. Drug Manufacturing Growth8/4/2026
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a $300 million expansion of its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing total U.S. manufacturing investment to more than $1 billion. The expansion will increase BeOne's production capacity to manufacture its medicines and is expected to create approximately 120 new full-time jobs. The investment supports the continued advancement of BeOne's deep oncology pipeline of more than 35 clinical and commercial-stage assets.
-
Why GSK Is Investing £400 Million In Cambridge8/4/2026
GSK plc (LSE/NYSE: GSK) today announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline. The new 300,000 square foot site, on the Cambridge Biomedical Campus in the heart of the UK’s life sciences “Golden Triangle,” will be home to GSK’s R&D operations in the UK and more than 1,000 GSK scientists.
-
Virtual Pharma Expo Launches Searchable Six-Year Equipment Demo Archive Ahead Of September Solid Dosage Event7/30/2026
Virtual Pharma Expo has launched a redesigned website that gives pharmaceutical manufacturing teams one place to watch every past equipment demonstration and register for upcoming live events.
